Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial.

MLA

Thibaudin, Marion, et al. “Safety and Efficacy of Trifluridine/Tipiracil +/− Bevacizumab plus XB2001 (Anti-IL-1α Antibody): A Single-Center Phase 1 Trial.” Signal Transduction & Targeted Therapy, vol. 10, no. 1, Jan. 2025, pp. 1–13. EBSCOhost, https://doi.org/10.1038/s41392-024-02116-4.

APA

Thibaudin, M., Roussot, N., Burlot, C., Schmitt, A., Vincent, J., Tharin, Z., Bengrine, L., Bellio, H., Bertaut, A., Hampe, L., Daumoine, S., Rederstorff, E., Peroz, M., Huppe, T., Derangère, V., Rageot, D., Simard, J., Truntzer, C., Fumet, J. D., & Ghiringhelli, F. (2025). Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial. Signal Transduction & Targeted Therapy, 10(1), 1–13. https://doi.org/10.1038/s41392-024-02116-4

Chicago

Thibaudin, Marion, Nicolas Roussot, Chloé Burlot, Antonin Schmitt, Julie Vincent, Zoé Tharin, Leila Bengrine, et al. 2025. “Safety and Efficacy of Trifluridine/Tipiracil +/− Bevacizumab plus XB2001 (Anti-IL-1α Antibody): A Single-Center Phase 1 Trial.” Signal Transduction & Targeted Therapy 10 (1): 1–13. doi:10.1038/s41392-024-02116-4.